Your browser doesn't support javascript.
loading
RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse.
Oza, Bhavna; Frangou, Eleni; Smith, Ben; Bryant, Hanna; Kaplan, Rick; Choodari-Oskooei, Babak; Powles, Tom; Stewart, Grant D; Albiges, Laurence; Bex, Axel; Choueiri, Toni K; Davis, Ian D; Eisen, Tim; Fielding, Alison; Harrison, David; McWhirter, Anita; Mulhere, Salena; Nathan, Paul; Rini, Brian; Ritchie, Alastair; Scovell, Sarah; Shakeshaft, Clare; Stockler, Martin R; Thorogood, Nat; Parmar, Mahesh K B; Larkin, James; Meade, Angela.
Afiliação
  • Oza B; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, 2nd Floor 90 High Holborn, London WC1V 6LJ, UK. Electronic address: b.oza@ucl.ac.uk.
  • Frangou E; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, 2nd Floor 90 High Holborn, London WC1V 6LJ, UK.
  • Smith B; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, 2nd Floor 90 High Holborn, London WC1V 6LJ, UK.
  • Bryant H; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, 2nd Floor 90 High Holborn, London WC1V 6LJ, UK.
  • Kaplan R; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, 2nd Floor 90 High Holborn, London WC1V 6LJ, UK.
  • Choodari-Oskooei B; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, 2nd Floor 90 High Holborn, London WC1V 6LJ, UK.
  • Powles T; St Bartholomew's Hospital, W Smithfield, London EC1A 7B, UK.
  • Stewart GD; Department of Surgery, University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK.
  • Albiges L; Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94805 Villejuif, France.
  • Bex A; Royal Free London NHS Foundation Trust UCL Division of Surgery and Interventional Science, Pond Street, London NW3 2QG; Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Choueiri TK; Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, United States.
  • Davis ID; Monash University Eastern Health Clinical School, Level 2, 5 Arnold Street, Box Hill, VIC 3128, Australia; Department of Medical Oncology, Eastern Health, Melbourne, Australia; ANZUP Cancer Trials Group, Sydney, Australia.
  • Eisen T; Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge Biomedical Campus Hill's Road, Cambridge CB2 0QQ, UK.
  • Fielding A; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, 2nd Floor 90 High Holborn, London WC1V 6LJ, UK.
  • Harrison D; University of St Andrews, North Haugh, St Andrews KY16 9TF, UK.
  • McWhirter A; Royal Marsden Hospital, 203 Fulham Rd, Chelsea, London SW3 6JJ, UK.
  • Mulhere S; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, 2nd Floor 90 High Holborn, London WC1V 6LJ, UK.
  • Nathan P; Mount Vernon Cancer Centre, Rickmansworth Rd, Northwood HA6 2RN, UK.
  • Rini B; Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, United States.
  • Ritchie A; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, 2nd Floor 90 High Holborn, London WC1V 6LJ, UK.
  • Scovell S; St Bartholomew's Hospital, W Smithfield, London EC1A 7B, UK.
  • Shakeshaft C; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, 2nd Floor 90 High Holborn, London WC1V 6LJ, UK.
  • Stockler MR; ANZUP Cancer Trials Group, Sydney, Australia; NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW 2006, Australia.
  • Thorogood N; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, 2nd Floor 90 High Holborn, London WC1V 6LJ, UK.
  • Parmar MKB; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, 2nd Floor 90 High Holborn, London WC1V 6LJ, UK.
  • Larkin J; Royal Marsden Hospital, 203 Fulham Rd, Chelsea, London SW3 6JJ, UK.
  • Meade A; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, 2nd Floor 90 High Holborn, London WC1V 6LJ, UK.
Contemp Clin Trials ; 108: 106482, 2021 09.
Article em En | MEDLINE | ID: mdl-34538402
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Neoplasias Renais Tipo de estudo: Clinical_trials / Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Contemp Clin Trials Assunto da revista: MEDICINA / TERAPEUTICA Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Neoplasias Renais Tipo de estudo: Clinical_trials / Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Contemp Clin Trials Assunto da revista: MEDICINA / TERAPEUTICA Ano de publicação: 2021 Tipo de documento: Article